Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma

Sarah P. Psutka, Bradley C. Leibovich

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

The diagnosis of renal cell carcinoma is accompanied by intravascular tumor thrombus in up to 10% of cases, of which nearly one-third of patients also have concurrent metastatic disease. Surgical resection in the form of radical nephrectomy and caval thrombectomy represents the only option to obtain local control of the disease and is associated with durable oncologic control in approximately half of these patients. The objective of this clinical review is to outline the preoperative evaluation for, and operative management of patients with locally advanced renal cell carcinoma with venous tumor thrombi involving the inferior vena cava. Cornerstones of the management of these complex patients include obtaining high-quality imaging to characterize the renal mass and tumor thrombus preoperatively, with further intraoperative real-time evaluation using transesophageal echocardiography, careful surgical planning, and a multidisciplinary approach. Operative management of patients with high-level caval thrombi should be undertaken in high-volume centers by surgical teams with capacity for bypass and invasive intraoperative monitoring. In patients with metastatic disease at presentation, cytoreductive nephrectomy and tumor thrombectomy may be safely performed with simultaneous metastasectomy if possible. In the absence of level one evidence, neoadjuvant targeted therapy should continue to be viewed as experimental and should be employed under the auspices of a clinical trial. However, in patients with significant risk factors for postoperative complications and mortality, and especially in those with metastatic disease, consultation with medical oncology and frontline targeted therapy may be considered.

Original languageEnglish (US)
Pages (from-to)216-229
Number of pages14
JournalTherapeutic Advances in Urology
Volume7
Issue number4
DOIs
StatePublished - 2015

Fingerprint

Inferior Vena Cava
Renal Cell Carcinoma
Thrombosis
Neoplasms
Thrombectomy
Venae Cavae
Nephrectomy
Metastasectomy
Intraoperative Monitoring
Neoadjuvant Therapy
Medical Oncology
Transesophageal Echocardiography
Referral and Consultation
Clinical Trials
Kidney
Mortality

Keywords

  • metastasis
  • preoperative imaging
  • renal cell carcinoma
  • tumor thrombectomy
  • vascular reconstruction
  • vascular resection

ASJC Scopus subject areas

  • Urology

Cite this

Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma. / Psutka, Sarah P.; Leibovich, Bradley C.

In: Therapeutic Advances in Urology, Vol. 7, No. 4, 2015, p. 216-229.

Research output: Contribution to journalReview article

Psutka, Sarah P. ; Leibovich, Bradley C. / Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma. In: Therapeutic Advances in Urology. 2015 ; Vol. 7, No. 4. pp. 216-229.
@article{ee769a1433fd4e3f89a43a01eef66b8c,
title = "Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma",
abstract = "The diagnosis of renal cell carcinoma is accompanied by intravascular tumor thrombus in up to 10{\%} of cases, of which nearly one-third of patients also have concurrent metastatic disease. Surgical resection in the form of radical nephrectomy and caval thrombectomy represents the only option to obtain local control of the disease and is associated with durable oncologic control in approximately half of these patients. The objective of this clinical review is to outline the preoperative evaluation for, and operative management of patients with locally advanced renal cell carcinoma with venous tumor thrombi involving the inferior vena cava. Cornerstones of the management of these complex patients include obtaining high-quality imaging to characterize the renal mass and tumor thrombus preoperatively, with further intraoperative real-time evaluation using transesophageal echocardiography, careful surgical planning, and a multidisciplinary approach. Operative management of patients with high-level caval thrombi should be undertaken in high-volume centers by surgical teams with capacity for bypass and invasive intraoperative monitoring. In patients with metastatic disease at presentation, cytoreductive nephrectomy and tumor thrombectomy may be safely performed with simultaneous metastasectomy if possible. In the absence of level one evidence, neoadjuvant targeted therapy should continue to be viewed as experimental and should be employed under the auspices of a clinical trial. However, in patients with significant risk factors for postoperative complications and mortality, and especially in those with metastatic disease, consultation with medical oncology and frontline targeted therapy may be considered.",
keywords = "metastasis, preoperative imaging, renal cell carcinoma, tumor thrombectomy, vascular reconstruction, vascular resection",
author = "Psutka, {Sarah P.} and Leibovich, {Bradley C.}",
year = "2015",
doi = "10.1177/1756287215576443",
language = "English (US)",
volume = "7",
pages = "216--229",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma

AU - Psutka, Sarah P.

AU - Leibovich, Bradley C.

PY - 2015

Y1 - 2015

N2 - The diagnosis of renal cell carcinoma is accompanied by intravascular tumor thrombus in up to 10% of cases, of which nearly one-third of patients also have concurrent metastatic disease. Surgical resection in the form of radical nephrectomy and caval thrombectomy represents the only option to obtain local control of the disease and is associated with durable oncologic control in approximately half of these patients. The objective of this clinical review is to outline the preoperative evaluation for, and operative management of patients with locally advanced renal cell carcinoma with venous tumor thrombi involving the inferior vena cava. Cornerstones of the management of these complex patients include obtaining high-quality imaging to characterize the renal mass and tumor thrombus preoperatively, with further intraoperative real-time evaluation using transesophageal echocardiography, careful surgical planning, and a multidisciplinary approach. Operative management of patients with high-level caval thrombi should be undertaken in high-volume centers by surgical teams with capacity for bypass and invasive intraoperative monitoring. In patients with metastatic disease at presentation, cytoreductive nephrectomy and tumor thrombectomy may be safely performed with simultaneous metastasectomy if possible. In the absence of level one evidence, neoadjuvant targeted therapy should continue to be viewed as experimental and should be employed under the auspices of a clinical trial. However, in patients with significant risk factors for postoperative complications and mortality, and especially in those with metastatic disease, consultation with medical oncology and frontline targeted therapy may be considered.

AB - The diagnosis of renal cell carcinoma is accompanied by intravascular tumor thrombus in up to 10% of cases, of which nearly one-third of patients also have concurrent metastatic disease. Surgical resection in the form of radical nephrectomy and caval thrombectomy represents the only option to obtain local control of the disease and is associated with durable oncologic control in approximately half of these patients. The objective of this clinical review is to outline the preoperative evaluation for, and operative management of patients with locally advanced renal cell carcinoma with venous tumor thrombi involving the inferior vena cava. Cornerstones of the management of these complex patients include obtaining high-quality imaging to characterize the renal mass and tumor thrombus preoperatively, with further intraoperative real-time evaluation using transesophageal echocardiography, careful surgical planning, and a multidisciplinary approach. Operative management of patients with high-level caval thrombi should be undertaken in high-volume centers by surgical teams with capacity for bypass and invasive intraoperative monitoring. In patients with metastatic disease at presentation, cytoreductive nephrectomy and tumor thrombectomy may be safely performed with simultaneous metastasectomy if possible. In the absence of level one evidence, neoadjuvant targeted therapy should continue to be viewed as experimental and should be employed under the auspices of a clinical trial. However, in patients with significant risk factors for postoperative complications and mortality, and especially in those with metastatic disease, consultation with medical oncology and frontline targeted therapy may be considered.

KW - metastasis

KW - preoperative imaging

KW - renal cell carcinoma

KW - tumor thrombectomy

KW - vascular reconstruction

KW - vascular resection

UR - http://www.scopus.com/inward/record.url?scp=84937398678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937398678&partnerID=8YFLogxK

U2 - 10.1177/1756287215576443

DO - 10.1177/1756287215576443

M3 - Review article

VL - 7

SP - 216

EP - 229

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 4

ER -